People Background Check
Find People:

Stephen David Yanofsky, Age 721143 Dahlia Ct, Sunnyvale, CA 94086

Get Report
Known as:
Stephen D Yanofsky Stephen Dr Yanofsky Stephen Living Yanofsky Stephen Tr Yanofsky Steve D Yanofsky Stephen D Heegaard Stephen D Yanossky
Related to:
Nenita C Soberano 89

Stephen Yanofsky Phones & Addresses

1143 Dahlia Ct, Sunnyvale, CA 94086 (415) 852-0440

2310 Rock St, Mountain View, CA 94043 (650) 386-1046

Palm Desert, CA

10801 Rio Vista Rd, Forestville, CA 95436 (707) 887-0407

3781 Nathan Way, Palo Alto, CA 94303 (650) 852-0440 (650) 852-9394

San Francisco, CA

La Jolla, CA

San Mateo, CA

Santa Clara, CA

Sonoma, CA

Show more

Social networks

Stephen David Yanofsky

Linkedin

Work

Company: Tosk, inc. Nov 1, 2010 Position: Vice president research

Education

Degree: Bachelors, Bachelor of Science School / High School: Uc San Diego 1984 to 1988

Skills

Drug Discovery • High Throughput Screening • Assay Development • Biochemistry • Cell • Biotechnology • Cell Biology • Protein Purification • Protein Chemistry • Elisa • Cell Culture • Purification • Biomarkers • Flow Cytometry • Molecular Biology • Western Blotting • Immunoassays • Lifesciences • Protein Expression • Antibodies

Industries

Biotechnology

Mentions for Stephen David Yanofsky

Stephen Yanofsky resumes & CV records

Resumes

Stephen Yanofsky Photo 11

Vice President Research

Location:
1143 Dahlia Ct, Sunnyvale, CA 94086
Industry:
Biotechnology
Work:
Tosk, Inc.
Vice President Research Amunix Feb 2008 - Oct 2008
Director of Cell Biology Multispan, Inc. Oct 1, 2006 - Feb 1, 2008
Senior Scientist Receptron Jan 2002 - Jul 2005
Senior Scientist, Lead Discovery Affymax Oct 1, 1990 - Jun 1, 2001
Senior Scientist
Education:
Uc San Diego 1984 - 1988
Bachelors, Bachelor of Science University of California, San Francisco 1976 - 1983
Doctorates, Doctor of Philosophy, Biochemistry Uc San Diego 1971 - 1975
Bachelors, Bachelor of Science, Biology University of California
Skills:
Drug Discovery, High Throughput Screening, Assay Development, Biochemistry, Cell, Biotechnology, Cell Biology, Protein Purification, Protein Chemistry, Elisa, Cell Culture, Purification, Biomarkers, Flow Cytometry, Molecular Biology, Western Blotting, Immunoassays, Lifesciences, Protein Expression, Antibodies

Publications & IP owners

Us Patents

Antagonists Of Follicle Stimulating Hormone Activity

US Patent:
6426357, Jul 30, 2002
Filed:
Jul 31, 2000
Appl. No.:
09/629180
Inventors:
Randall A. Scheuerman - Santa Clara CA
Stephen D. Yanofsky - Palo Alto CA
Christopher P. Holmes - Saratoga CA
Derek MacLean - Mountain View CA
Beatrice Ruhland - Los Altos CA
Ronald W. Barrett - Saratoga CA
Jay E. Wrobel - Lawrenceville NJ
Ariamala Gopalsamy - Mahwah NJ
Assignee:
Affymax, Inc. - Palo Alto CA
International Classification:
A61K 31427
US Classification:
514369, 548182, 548187
Abstract:
The present invention provides a compound of the formula: and methods for using the same, wherein R , R , R , R and X are those defined herein.

Novel Bicyclic And Tricyclic Pyrrolidine Derivatives As Gnrh Antagonists

US Patent:
2002006, May 30, 2002
Filed:
May 18, 2001
Appl. No.:
09/860810
Inventors:
Ge Peng - Mountain View CA, US
Mark Gallop - Los Altos CA, US
Stephen Yanofsky - Palo Alto CA, US
Jeffrey Pelletier - Lafayette Hill PA, US
Daniel Green - Ambler PA, US
International Classification:
A61K031/4188
C07D487/14
US Classification:
514/387000, 548/302400
Abstract:
Bicyclic and tricyclic pyrrolidine derivatives are disclosed that are useful as antagonists of the GnRH receptor. Methods for using the novel compounds to treat GnRH-related disorders are also provided, as are pharmaceutical compositions and novel synthetic methods.

Peptides And Compounds That Bind To The Il-1 Receptor

US Patent:
5608035, Mar 4, 1997
Filed:
Feb 2, 1994
Appl. No.:
8/190788
Inventors:
Stephen D. Yanofsky - San Mateo CA
Ronald W. Barrett - Sunnyvale CA
David N. Baldwin - Palo Alto CA
Jeff W. Jacobs - San Mateo CA
Assignee:
Affymax Technologies N.V. - Middlesex
International Classification:
A61K 3800
A61K 3802
C07K 500
C07K 700
US Classification:
530324
Abstract:
Peptides that bind to the interleukin-1 type I receptor (IL-1RtI) can be used to assay the amount of IL-1R, or an IL-1R agonist or antagonist, in a sample and comprise a sequence of amino acids selected from the group consisting of (1) WXXXGZ. sub. 1 W (SEQ ID NO: 1) where Z. sub. 1 is L, I, A, or Q; (2) XXQZ. sub. 5 YZ. sub. 6 XX (SEQ ID NO: 6) where Z. sub. 5 is P or Aze where Aze is azetidine; and Z. sub. 6 is S, A, V, or L; and (3) Z. sub. 23 NZ. sub. 24 SZ. sub. 25 Z. sub. 26 Z. sub. 27 Z. sub. 28 Z. sub. 29 Z. sub. 30 L (SEQ ID NO: 17) where Z. sub. 23 is D or Y; Z. sub. 24 is D or S; Z. sub. 25 is S or W; Z. sub. 26 is S or Y; Z. sub. 27 is D or V; Z. sub. 28 is S or W; Z. sub. 29 is F or L; and Z. sub. 30 is D or L; and where each amino acid is indicated by standard one letter abbreviation; and each X can be selected from any one of the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids.

Peptides And Compounds That Bind To The Il-1 Receptor

US Patent:
5767234, Jun 16, 1998
Filed:
Feb 1, 1995
Appl. No.:
8/383474
Inventors:
Stephen D. Yanofsky - San Mateo CA
Ronald W. Barrett - Sunnyvale CA
David Baldwin - Palo Alto CA
Jeff W. Jacobs - San Mateo CA
Assignee:
Affymax Technologies, N.V. - Greenford
International Classification:
A61K 3800
C07K 500
C07K 700
US Classification:
530327
Abstract:
Peptides that bind to the interleukin-1 type I receptor (IL-1RtI) can be used to assay the amount of IL-1R, or an IL-1R agonist or antagonist, in a sample and comprise a sequence of amino acids selected from the group consisting of (1) WXXXGZ. sub. 1 W (SEQ ID NO: 2) where Z. sub. 1 is L, I, A, or Q; (2) XXQZ. sub. 5 YZ. sub. 6 XX where (SEQ ID NO: 1) Z. sub. 5 is P or Aze where Aze is azetidine; and Z. sub. 6 is S, A, V, or L; and (3) Z. sub. 23 NZ. sub. 24 SZ. sub. 25 Z. sub. 26 Z. sub. 27 Z. sub. 28 Z. sub. 29 Z. sub. 30 L (SEQ ID NO: 313) where Z. sub. 23 is D or Y; Z. sub. 24 is D or S; Z. sub. 25 is S or W; Z. sub. 26 is S or Y; Z. sub. 27 is D or V; Z. sub. 28 is S or W; Z. sub. 29 is F or L; and Z. sub. 30 is D or L; and where each amino acid is indicated by standard one letter abbreviation; and each X can be selected from any one of the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids.

Peptides And Compounds That Bind To The Il-1 Receptor

US Patent:
5880096, Mar 9, 1999
Filed:
Jun 5, 1995
Appl. No.:
8/463076
Inventors:
Ronald W. Barrett - Saratoga CA
Stephen D. Yanofsky - San Mateo CA
Assignee:
Affymax Technologies N.V. - Greenford
International Classification:
A61K 3800
A61K 3804
US Classification:
514 15
Abstract:
Peptides that bind to the interleukin-1 type I receptor (IL-1RtI) can be used to assay the amount of IL-1R, or an IL-1R agonist or antagonist, in a sample and comprise a sequence of amino acids selected from the group consisting of (1) WXXXGZ. sub. 1 W where Z. sub. 1 is L, I, A, or Q (SEQ ID NO:2); (2) XXQZ. sub. 5 YZ. sub. 6 XX where Z. sub. 5 is P or Aze where Aze is azetidine; and Z. sub. 6 is S, A, V, or L (SEQ ID NO:1); and (3) Z. sub. 23 NZ. sub. 24 SZ. sub. 25 Z. sub. 26 Z. sub. 27 Z. sub. 28 Z. sub. 29 Z. sub. 30 L where Z. sub. 23 is D or Y; Z. sub. 24 is D or S; Z. sub. 25 is S or W; Z. sub. 26 is S or Y; Z. sub. 27 is D or V; Z. sub. 28 is S or W; Z. sub. 29 is F or L; and Z. sub. 30 is D or L (SEQ ID NO:27); and where each amino acid is indicated by standard one letter abbreviation; and each X can be selected from any one of the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids. Also provided are peptides which bind to the IL-1RtI, which are 11 to 40 amino acids in length, which comprise the core sequence of amino acids: Z. sub. 31 XWZ. sub. 32 Z. sub. 33 Z. sub. 34 Z. sub. 35 Z. sub. 36 QZ. sub. 37 Z. sub.

Peptides And Compounds That Bind To The Il-1 Receptor

US Patent:
5786331, Jul 28, 1998
Filed:
Jun 5, 1995
Appl. No.:
8/465391
Inventors:
Ronald W. Barrett - Sunnyvale CA
Stephen D. Yanofsky - San Mateo CA
David Baldwin - Palo Alto CA
Jeff W. Jacobs - San Mateo CA
Phillipe R. Bovy - Los Altos CA
Ellen M. Leahy - San Leandro CA
Richard S. Pottorf - West Chester OH
Assignee:
Affymax Technologies N.V. - Greenford
Hoechst Marion Roussel, Inc. - Kansas City MO
International Classification:
A61K 3808
A61K 3800
C07K 704
US Classification:
514 15
Abstract:
Peptides that bind to the interleukin-1 type I receptor (IL-1RtI) can be used to assay the amount of IL-1R, or an IL-1R agonist or antagonist, in a sample and comprise a sequence of amino acids selected from the group consisting of (1) WXXXGZ. sub. 1 W where Z. sub. 1 is L, I, A, or Q; (2) XXQZ. sub. 5 YZ. sub. 6 XX where Z. sub. 5 is P or Aze where Aze is azetidine; and Z. sub. 6 is S, A, V, or L; and (3) Z. sub. 23 NZ. sub. 24 SZ. sub. 25 Z. sub. 26 Z. sub. 27 Z. sub. 28 Z. sub. 29 Z. sub. 30 L where Z. sub. 23 is D or Y; Z. sub. 24 is D or S; Z. sub. 25 is S or W; Z. sub. 26 is S or Y; Z. sub. 27 is D or V; Z. sub. 28 is S or W; Z. sub. 29 is F or L; and Z. sub. 30 is D or L; and where each amino acid is indicated by standard one letter abbreviation; and each X can be selected from any one of the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids. Also provided are peptides which bind to the IL-1RtI, which are 11 to 40 amino acids in length, which comprise the core sequence of amino acids: Z. sub. 31 XWZ. sub. 32 Z. sub. 33 Z. sub. 34 Z. sub. 35 Z. sub. 36 QZ. sub. 37 Z. sub. 38 where each letter represents the standard one letter abbreviation for an amino acid or an analog thereof; X is selected from the group of natural or unnatural amino acids; Z. sub.

Peptides And Compounds That Bind To The Il-1 Receptor

US Patent:
5861476, Jan 19, 1999
Filed:
Jun 5, 1995
Appl. No.:
8/464538
Inventors:
Ronald W. Barrett - Sunnyvale CA
Stephen D. Yanofsky - San Mateo CA
David Baldwin - Palo Alto CA
Jeff W. Jacobs - San Mateo CA
Phillipe R. Bovy - Los Altos CA
Ellen M. Leahy - San Leandro CA
Richard S. Pottorf - West Chester OH
Assignee:
Affymax Technologies N.V. - Greenford
Hoechst Marion Roussel, Inc. - Kansas City MO
International Classification:
C07K 704
A61K 3800
A61K 3804
US Classification:
530527
Abstract:
Peptides that bind to the interleukin-1 type I receptor (IL-1RtI) can be used to assay the amount of IL-1R, or an IL-1R agonist or antagonist, in a sample and comprise a sequence of amino acids selected from the group consisting of (1) WXXXGZ. sub. 1 W where Z. sub. 1 is L, I, A, or Q; (2) XXQZ. sub. 5 YZ. sub. 6 XX where Z. sub. 5 is P or Aze where Aze is azetidine; and Z. sub. 6 is S, A, V, or L; and (3) Z. sub. 23 NZ. sub. 24 SZ. sub. 25 Z. sub. 26 Z. sub. 27 Z. sub. 28 Z. sub. 29 Z. sub. 30 L where Z. sub. 23 is D or Y; Z. sub. 24 is D or S; Z. sub. 25 is S or W; Z. sub. 26 is S or Y; Z. sub. 27 is D or V; Z. sub. 28 is S or W; Z. sub. 29 is F or L; and Z. sub. 30 is D or L; and where each amino acid is indicated by standard one letter abbreviation; and each X can be selected from any one of the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids. Also provided are peptides which bind to the IL-1RtI, which are 11 to 40 amino acids in length, which comprise the core sequence of amino acids: Z. sub. 31 XWZ. sub. 32 Z. sub. 33 Z. sub. 34 Z. sub. 35 Z. sub. 36 QZ. sub. 37 Z. sub. 38 where each letter represents the standard one letter abbreviation for an amino acid or an analog thereof; X is selected from the group of natural or unnatural amino acids; Z. sub.

Modulators Of Ras Gtpase

US Patent:
2022022, Jul 21, 2022
Filed:
Apr 13, 2020
Appl. No.:
17/439989
Inventors:
- Mountain View CA, US
William A. Garland - Mountain View CA, US
Stephen D. Yanofsky - Mountain View CA, US
Brian D. Frenzel - Mountain View CA, US
Philip Liaw - Mountain View CA, US
Annie L. Lennek - Mountain View CA, US
International Classification:
C07D 405/14
C07D 239/84
C07D 401/04
C07D 401/12
C07D 401/14
C07D 405/04
C07D 413/04
C07D 413/14
C07D 471/04
Abstract:
RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.

Possible Relatives

Linda S Yanofsky  Steven F Yanofsky  Stephen R Stanek  Stephen S Stanfill  Stephen M Stanford  Stephen L Joiner  Stephen H Jones  Stephen D Stanger  Stephen J Stanko  Stephen E Stansbury 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.